70-110 mg/dl 5-10 10-40 7-20 catecholamine transportersglut4 1997 Creviston & Quinn, 2001Dela et al., 1994Garrett & Kirkendall, 2000 2000 16 uptake GLUT4 GLUT4 40 free fatty acid; FFA 2001Garrett Kirkendall2000 23
insulin glucagon CRF 2001 10 1991 Helmrich 5990 cohort study 500Kcal 6% 24% 8633 30 20% 40% 3.7 1.9 Wei et al., 1999 2-1 24
Bogardus et al.,1984ruderman, Ganda, & Johansen, 1979 1979 Ruderman 14~38 1984 Trovati 5 6 7 1 50~60% VO 2max 48 OGTT glucose AUCarea under curveogtt glucose 90 120 OGTT insulin AUC OGTT insulin Rice 1999 50~85%VO 2max 5 1 5~10 OGTT OGTT glucose AUC OGTT insulin AUC c-peptides Dela et al., 1994Ganong, 2001 GLUT4 Wojtaszewski & Hansen, 2002 25
36 residual effects Mikins, Sonnie, Farrell, Tronier, & Galbo, 1988 Segal 1991 5~10 OGTT insulin AUC chronic effects Gunton, Davies, Wilmshurist, Fukher, & McElduff2002 1979 Saltin 48 3-12 2 26
60 Campaigne 1997 30 HbA 1C Dela et al., 1994Lampman et al., 1987Lehmann et al., 1995Rice et al., 1999Trovati et al., 1984Walker, Piers, Putt, Jones, & O Dea, 1999 Fujinuma 1999 4-6 50-60 22.2% 25.9% Powers & Howley, 2001 27
Creviston & Quinn, 2001Lampman et al., 1987Rice et al., 1999Ruderman et al., 1979Trovati et al., 1984 Lahmann 1995 16 3 3 50~70% VO 2max 0.96 0.92 35.2 33.0 Walker 1999 12 5 Dela et al., 1994 Yananouchi et al., 1995 TC TG LDL HDL Ganong, 2001 TC>=240 mg/dltg>400 mg/dlldl>160 mg/dl high risktc 200-239 mg/dltg 200-399 mg/dl LDL 130-159 mg/dl borderline high risk HDL 35 mg/dl ACSM, 2000 28
Powers & Howley, 2001 Ruderman et al., 1979Lahmann 1995 16 3 TG HDL Tanaka 2000 151 3 4-6 40-45 70-75%HR max TCLDL HDL Lampman 1987 IGT 9 12 Sgouraki, A. Tsopanakis, & C. Tsopanakis, 2001 12 12 Powers & Howley, 2001 29
1996 2000Bogardus et al., 1984Milani & Lavie, 1998 Dela 1994 7 9 6 30 70%HR max Lampman et al., 1987Lehmann et al., 1997Rice et al., 1999Trovati et al., 1984 Tanaka et al., 2000 30
2-1. 1979Ruderman et type 2 DM bicycle VO 2max 15 al. erdermeter 5 (p<0.025)oral glucose tolerance 20-30 test insulin 300-750kpm(p<0.025)cholesterol 14-38 p<0.001tg p<0.01 1979 Saltin et al. 48type 2 DM 3-12 2 60 OGTT p<0.001vo 2max 20 n=25 n=12 n=11 p<0.001 muscle capillary supply p<0.001 metabolic potential HK35 SDH75 (p<0.001) 1984 Bogardus et al. Impaired glucose tolerance type 2 12 VO 2max p<0.025 3 60 DM 18 p<0.025 p<0.025 20-30 p<0.025 n=10 75HR max c-peptide p<0.025 n=8 1994 Dela et al. 7 NIDDM 9 VO2max 8 6 30 p<0.05 70HR max BMI p<0.05 p<0.05 GLUT4 GLUT4 mrna p<0.05 1999 Walker et al. 31 type 2 DM 5 60 type 2 DM BMI (n=11)20 1.6 p<0.05 12 HgbA 1C (p<0.05)ldl p<0.05cholesteral (p<0.005) HgbA 1C p<0.05 1984 Reitman et al 6 type 2 6-10 DM 5-6 p<0.05 20-40 p<0.05 60-90% VO 2max 1997 Lehmann et al 20type 1 DM waist-to-hip ratio 50-70% VO 2max p<0.001vo 2max 45 p<0.001 p<0.001 1984 Trovati et al. 5 type 2 DM 6 VO 2max 15, 7 60 p<0.025,hgba 1C 50-60%VO 2max p<0.05 p<0.025 OGTT 31
1987 Lampman et al. 19 29-63y/o type 3 VO 2max 2 DM 30-40 85 HR max 9 p<0.01 5 peak VO 2 19 p<0.05 60 p<0.05bmi p<0.001 n=10 50-85%HR max waist-to-hip ratio (p<0.05) 5-10 OGTT p>0.02 n=10 30 (n=9) 1999 Rice et al. 29 2-2 Dubbert 1994 28 10 Milani 1992 50 SF-36 SF-36 12 32
1999 27 10 3-5 30-50 Cotman & Engessor-Cesar, 2002 1979 Greist 2000Elizabeth, Doyne, Kent, Ilona, & Robbert, 1987Gowans et al., 2001 1999 33
Cotman Engessor-Cesar2002 BDNFBrain-derived neurotrophic factor 2001 2-2 1996 30 3 p=0.008 12 p<.001 p<.0001 1999 27 12 p<.01 15 3-5 30-50 p=.01 2000 40 3 30-50 8 p<.01 p<.05 2001 10 1 5 10 3 1 15-20 p=.001 2001 Karper et al. 13 FMS(fibromyalgia 6-18 3 syndrome) 30 12-13 p<.05 p<.05 34
1987 Elizabeth et al. 40 HDRSBDI 3-5 LDAL p<.05 1998 Segar et al. 24 10 41.8 (BDI)p<.01 (stait 4 anxiety inventory, STAI) 30 p<.02 p<.01 Rice et al., 1999Trovati et al., 1984 35